A one-year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes.
A one year study to assess the safety and efficacy of the inverse antagonist taranabant CB1R in overweight and obese patients with type 2 diabetes